Catalog No.
DHD38501
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
scFv-His
Clonality
Monoclonal
Target
Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22
Concentration
0.85mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P20273
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CAT-8015, GCR-8015, HA22, moxetumomab pasudotox -tdfk, CAS: 1020748-57-5
Clone ID
Moxetumomab
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia, PMID: 30030507
Moxetumomab Pasudotox: First Global Approval, PMID: 30357593
Moxetumomab Pasudotox, PMID: 31644208
Moxetumomab pasudotox for the treatment of hairy cell leukemia, PMID: 31045462
Moxetumomab Pasudotox, PMID: 30371998
Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia, PMID: 31099793
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations, PMID: 31134324
Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemia, PMID: 30917739
Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia, PMID: 31298972
Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval, PMID: 31594764
Hairy cell leukemia: present and future directions, PMID: 31068044
Deamidation in Moxetumomab Pasudotox Leading to Conformational Change and Immunotoxin Activity Loss, PMID: 32534028
[Hairy cell leukemia], PMID: 31447330
Correction to: Moxetumomab Pasudotox: First Global Approval, PMID: 30612318
Treatment of hairy cell leukemia, PMID: 32893700
Moxetumomab Pasudotox in Hairy Cell Leukaemia: A Profile of Its Use, PMID: 34383256
Update on hairy cell leukemia, PMID: 29742076
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox, PMID: 22003067
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia, PMID: 31628266
Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia, PMID: 32077130
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia, PMID: 31944549
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up, PMID: 29487070
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia, PMID: 28983018
A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains, PMID: 31676342
Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia, PMID: 28449314
5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox, PMID: 29432154
Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys, PMID: 23090886
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial, PMID: 33627164
Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia, PMID: 34030585
Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction, PMID: 32959985
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia, PMID: 28616864
Collateral Damages by Magic Bullets: Hemolytic Uremic and Capillary Leak Syndromes After Moxetumomab Pasudotox Therapy, PMID: 31233704
An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox, PMID: 27220271
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia, PMID: 22355053
Development of Recombinant Immunotoxins for Hairy Cell Leukemia, PMID: 32756468
Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities, PMID: 33076544
Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox, PMID: 34202156
Immunoconjugates in the management of hairy cell leukemia, PMID: 26614902
The pharmacological management of hairy cell leukemia, PMID: 32378970
Critical Issues in the Development of Immunotoxins for Anticancer Therapy, PMID: 31669121
Hairy cell leukemia-new genes, new targets, PMID: 23892906
Hairy Cell Leukemia Treatment Approved, PMID: 30262591
How I manage patients with hairy cell leukaemia, PMID: 28146266
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4), PMID: 29572070
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma, PMID: 31500657
Potential breakthroughs with investigational drugs for hairy cell leukemia, PMID: 26329588
Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation, PMID: 32695104
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant, PMID: 30841702
Novel therapeutic options for relapsed hairy cell leukemia, PMID: 25563425
New monoclonal antibodies for the treatment of acute lymphoblastic leukemia, PMID: 27521873
For research use only. Not for human or drug use.
